BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37610690)

  • 21. Antitumor Effect of Simvastatin in Combination With DNA Methyltransferase Inhibitor on Gastric Cancer
    Xia Y; Jin Y; Cui D; Wu X; Song C; Jin W; Huang H
    Front Pharmacol; 2022; 13():860546. PubMed ID: 35517821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Miltirone induces cell death in hepatocellular carcinoma cell through GSDME-dependent pyroptosis.
    Zhang X; Zhang P; An L; Sun N; Peng L; Tang W; Ma D; Chen J
    Acta Pharm Sin B; 2020 Aug; 10(8):1397-1413. PubMed ID: 32963939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The natural compound from Garcinia bracteata mainly induces GSDME-mediated pyroptosis in esophageal cancer cells.
    Tan JQ; Li Z; Chen G; Wu M; Feng JL; Kong SY; Shi XQ; Zhang HM; Lao YZ; Zhou H; Zhang L; Xu HX
    Phytomedicine; 2022 Jul; 102():154142. PubMed ID: 35623158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.
    Risdon EN; Chau CH; Price DK; Sartor O; Figg WD
    Oncologist; 2021 Jan; 26(1):e115-e129. PubMed ID: 32790034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ionizing Radiation Triggers the Antitumor Immunity by Inducing Gasdermin E-Mediated Pyroptosis in Tumor Cells.
    Cao W; Chen G; Wu L; Yu KN; Sun M; Yang M; Jiang Y; Jiang Y; Xu Y; Peng S; Han W
    Int J Radiat Oncol Biol Phys; 2023 Feb; 115(2):440-452. PubMed ID: 35918054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breaking the Iron Homeostasis: A "Trojan Horse" Self-Assembled Nanodrug Sensitizes Homologous Recombination Proficient Ovarian Cancer Cells to PARP Inhibition.
    Li Y; Cen Y; Fang Y; Tang S; Li S; Ren Y; Zhang H; Lu W; Xu J
    ACS Nano; 2022 Aug; 16(8):12786-12800. PubMed ID: 35920396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natural product triptolide induces GSDME-mediated pyroptosis in head and neck cancer through suppressing mitochondrial hexokinase-ΙΙ.
    Cai J; Yi M; Tan Y; Li X; Li G; Zeng Z; Xiong W; Xiang B
    J Exp Clin Cancer Res; 2021 Jun; 40(1):190. PubMed ID: 34108030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer.
    Ghonim MA; Ibba SV; Tarhuni AF; Errami Y; Luu HH; Dean MJ; El-Bahrawy AH; Wyczechowska D; Benslimane IA; Del Valle L; Al-Khami AA; Ochoa AC; Boulares AH
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.
    Ma X; Dang C; Min W; Diao Y; Hui W; Wang X; Dai Z; Wang X; Kang H
    Breast Cancer Res Treat; 2019 Jul; 176(1):109-117. PubMed ID: 30989461
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Hu Z; Lai Y; Ma C; Zuo L; Xiao G; Gao H; Xie B; Huang X; Gan H; Huang D; Yao N; Feng B; Ru J; Chen Y; Cai D
    Food Sci Nutr; 2022 Jan; 10(1):21-38. PubMed ID: 35035907
    [No Abstract]   [Full Text] [Related]  

  • 31. PARP inhibitors in advanced prostate cancer: when to use them?
    Díaz-Mejía N; García-Illescas D; Morales-Barrera R; Suarez C; Planas J; Maldonado X; Carles J; Mateo J
    Endocr Relat Cancer; 2021 Jul; 28(8):T79-T93. PubMed ID: 34256353
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. OTUD4-mediated GSDME deubiquitination enhances radiosensitivity in nasopharyngeal carcinoma by inducing pyroptosis.
    Di M; Miao J; Pan Q; Wu Z; Chen B; Wang M; Zhao J; Huang H; Bai J; Wang Q; Tang Y; Li Y; He J; Xiang T; Weng D; Wang L; Xia J; Zhao C
    J Exp Clin Cancer Res; 2022 Nov; 41(1):328. PubMed ID: 36411454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer.
    Unlu S; Kim JW
    Curr Oncol Rep; 2022 Nov; 24(11):1619-1631. PubMed ID: 35931885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PARP1 inhibitors induce pyroptosis via caspase 3-mediated gasdermin E cleavage.
    Kim C; Wang XD; Jang S; Yu Y
    Biochem Biophys Res Commun; 2023 Feb; 646():78-85. PubMed ID: 36706709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib.
    Bianchi A; Lopez S; Altwerger G; Bellone S; Bonazzoli E; Zammataro L; Manzano A; Manara P; Perrone E; Zeybek B; Han C; Menderes G; Ratner E; Silasi DA; Huang GS; Azodi M; Newberg JY; Pavlick DC; Elvin J; Frampton GM; Schwartz PE; Santin AD
    Gynecol Oncol; 2019 Oct; 155(1):144-150. PubMed ID: 31434613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor Intrinsic PD-L1 Promotes DNA Repair in Distinct Cancers and Suppresses PARP Inhibitor-Induced Synthetic Lethality.
    Kornepati AVR; Boyd JT; Murray CE; Saifetiarova J; de la Peña Avalos B; Rogers CM; Bai H; Padron AS; Liao Y; Ontiveros C; Svatek RS; Hromas R; Li R; Hu Y; Conejo-Garcia JR; Vadlamudi RK; Zhao W; Dray E; Sung P; Curiel TJ
    Cancer Res; 2022 Jun; 82(11):2156-2170. PubMed ID: 35247877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CXCR4-targeted nanotoxins induce GSDME-dependent pyroptosis in head and neck squamous cell carcinoma.
    Rioja-Blanco E; Arroyo-Solera I; Álamo P; Casanova I; Gallardo A; Unzueta U; Serna N; Sánchez-García L; Quer M; Villaverde A; Vázquez E; León X; Alba-Castellón L; Mangues R
    J Exp Clin Cancer Res; 2022 Feb; 41(1):49. PubMed ID: 35120582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ex vivo treatment of prostate tumor tissue recapitulates in vivo therapy response.
    Zhang W; van Weerden WM; de Ridder CMA; Erkens-Schulze S; Schönfeld E; Meijer TG; Kanaar R; van Gent DC; Nonnekens J
    Prostate; 2019 Mar; 79(4):390-402. PubMed ID: 30520109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer.
    Lai SW; Bamodu OA; Chen JH; Wu AT; Lee WH; Chao TY; Yeh CT
    Cells; 2020 Apr; 9(4):. PubMed ID: 32276472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.